<DOC>
	<DOCNO>NCT00861094</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , oxaliplatin , fluorouracil , leucovorin , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . PURPOSE : This randomized phase II/III trial study radiation therapy two different combination chemotherapy regimens compare well work first-line therapy treat patient esophageal cancer remove surgery .</brief_summary>
	<brief_title>Radiation Therapy + Combination Chemotherapy 1st-Line Therapy Patients With Inoperable Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess feasibility radiochemotherapy comprise oxaliplatin , fluorouracil , leucovorin calcium ( FOLFOX regimen ) vs fluorouracil cisplatin ( Herskovic regimen ) patient inoperable esophageal cancer . ( Phase II ) - To assess endoscopic complete response rate patient treat regimen . ( Phase II ) - To compare event-free survival patient treat regimen . ( Phase III ) Secondary - To assess toxicity profile regimens use NCI CTC v2.0 criterion . ( Phase II ) - To compare overall survival , endoscopic complete response rate , incidence grade 3-4 toxicity , time treatment failure patient treat regimen . ( Phase III ) - To evaluate quality life patient use EORTC QLQ-C30 ( version 3 ) validate disease-specific module EORTC QLQ-OES18 . ( Phase III ) OUTLINE : This multicenter study . Patients stratify accord histological type ( adenocarcinoma adenosquamous carcinoma v squamous cell carcinoma ) , pretreatment weight loss within past 6 month ( grade 1 [ &lt; 10 % ] v grade 2 [ ≥ 10 % ] ) , ECOG performance status ( 0 vs 1 v 2 ) , participate center . Patients randomize 1 2 treatment arm . - Arm I ( modify FOLFOX 4 regimen ) : Patients undergo radiotherapy 5 day week 5 week . Beginning concurrently radiotherapy , patient receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 . Treatment chemotherapy repeat every 2 week 6 course absence disease progression unacceptable toxicity . - Arm II ( Herskovic regimen ) : Patients undergo radiotherapy arm I . Patients also receive cisplatin IV continuously 24 hour day 1 fluorouracil IV continuously 96 hour day 1-4 week 1 , 5 , 8 , 11 absence disease progression unacceptable toxicity . Quality life assess baseline , periodically study therapy , every 6 month 1 year annually 3 year completion study therapy . After completion study therapy , patient follow 4 week every 3-6 month disease progression . PROJECTED ACCRUAL : A total 97 patient accrue phase II portion study . A total 169 patient accrued phase III portion study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma , squamous cell carcinoma , adenosquamous carcinoma esophagus Locally advanced disease ( T , N0 N1 , M0 M1a ) No metastatic disease , except tumor involvement upper third esophagus cervical esophageal tumor regional node , tumor involvement low third esophagus celiac node ( M1a ) Cervical primary tumor positive supraclavicular cervical lymph node ( define N1 ) allow No radiographic evidence enlarge ( ≥ 1.5 cm ) celiac lymph node CT scan echography No small cell undifferentiated carcinoma esophagus No multiple carcinoma esophagus ( i.e. , &gt; 1 esophageal tumor ) No cardia tumor ( Siewert II ) gastric tumor extension esophagus ( Siewert III ) Esophageal tumor extension cardia ( Siewert I ) ( center tumor lie &gt; 1 cm5 cm gastroesophageal junction ) allow Inoperable disease OR surgery contraindicate No tracheoesophageal fistula invasion tracheobronchial tree PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL ( transfusion allow ) Creatinine &lt; 15 mg/L Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 2.5 time ULN Prothrombin time ≥ 60 % Not pregnant nursing Fertile patient must use effective contraception Caloric intake sufficient ( i.e. , &gt; 1,000 Kcal/m²/day ) ( orally gastrostomy ) No weight loss &gt; 20 % normal body weight within past 3 month No complete dysphagia No exclusive requirement parenteral nutrition No peripheral neuropathy &gt; grade 1 No sensitive peripheral neuropathy functional impairment No auditory disorder No prior malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix stage I II nodenegative head neck cancer curatively treat &gt; 3 year ago No myocardial infarction within past 6 month Patients myocardial infarction &gt; 6 month ago eligible provide transient ischemia thallium myocardial scintigraphy patient able undergo chemotherapy , determine cardiologist No serious illness medical condition ( e.g. , symptomatic coronary disease , leave ventricular failure , uncontrolled infection ) No stage IIIV arterial disease , accord DE LERICHE FONTAINE classification No geographical , social , psychological circumstance prevent regular followup PRIOR CONCURRENT THERAPY : No prior treatment esophageal cancer ( e.g. , surgery , chemotherapy , radiotherapy ) No prior cervical , thoracic , abdominal radiotherapy field overlap propose esophageal radiotherapy field More 30 day since prior experimental drug participation another clinical trial No concurrent anticancer therapy No concurrent phenytoin yellow fever vaccine No concurrent highdose , longterm corticosteroid No concurrent calcium gluconate/magnesium sulfate infusion No concurrent hematopoietic growth factor No concurrent esophageal dilatation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>